Navigation Links
Anadys Pharmaceuticals Augments Management Team and Board of Directors
Date:1/6/2011

SAN DIEGO, Jan. 6, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced the following additions and changes to its management team and Board of Directors:

  • Kevin L. Eastwood has joined Anadys as Senior Vice President, Corporate Development
  • James Appleman, Ph.D. has been promoted to Senior Vice President, Research and Chief Scientific Officer
  • James L. Freddo, M.D., Anadys' Senior Vice President, Drug Development and Chief Medical Officer, has been appointed to the Company's Board of Directors
  • Stelios Papadopoulos, Ph.D. has been named Chairman of the Board

"I am delighted with the addition of Kevin Eastwood to our management team and the additional responsibilities for Drs. Appleman, Freddo and Papadopoulos," said Steve Worland, Ph.D., Anadys' President and CEO.  "With these changes in place, we are well-positioned to execute our corporate objectives in the coming year."

Mr. Eastwood, who joins Anadys from Ambrx, Inc., will be responsible for the Company's business development and strategic planning activities, reporting to Steve Worland, Ph.D., President and Chief Executive Officer.  Mr. Eastwood has held a number of prior business development positions, including the senior corporate development positions at Ambrx, Inc. and Achillion Pharmaceuticals, Inc.  In these positions he was responsible for executing business transactions with a number of leading biotechnology and pharmaceutical companies, including Pfizer, Inc., Merck and Co., Inc., Eli Lilly and Company, and Gilead Sciences, Inc.  Mr. Eastwood began his pharmaceuticals career in sales and marketing at Marion Laboratories and transitioned to business development while at Agouron Pharmaceuticals, Inc., now a part of Pfizer.  He holds a B.S. in Biology from Missouri State University. &
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Anadys Pharmaceuticals to Present at the Lazard Healthcare Conference
2. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2009 Financial Results
3. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
4. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
5. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
6. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
7. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
8. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
9. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
10. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
11. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 4, 2015  Brooklyn residents now have a new ... pain and injuries. Nunzio Saulle , M.D., a ... of his NJS Physical Medicine and Rehabilitation (PM&R) practice ... March 5, 2015. Health Plus Management, LLC is managing ... at 1178 Flatbush Avenue. This new PM&R practice will ...
(Date:3/4/2015)... March 4, 2015 /CNW/ - Resverlogix Corp. (TSX:RVX) ... completed a collaborative research program with Emerald ... Fast Collective Evolution Technology (FACET), Emerald Logic ... measurements obtained from each of 798 patients ... clinical trials ASSERT, SUSTAIN and ASSURE. The ...
(Date:3/4/2015)... Pa. , March 4, 2015 /PRNewswire/ ... services and technology provider, today announced that ... 10 countries convened at its annual European ... to discuss the use of ... challenges. BioClinica,s eClinical technologies include: the Microsoft ...
(Date:3/4/2015)... 2015 Lancée par ... en décembre 2011, l,étude collaborative française ... qui compare   l es microsphères en ... dans le carcinome hépatocellulaire avancé, a recruté plus ... avancé   ; les résultats sont attendus fin ...
Breaking Biology Technology:NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 2BioClinica Teams With Pharma To Tackle Clinical Trial Challenges In Europe 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6
... /Xinhua-PRNewswire-FirstCall/ -- American Oriental,Bioengineering, Inc. (NYSE: AOB ), ... manufacture and commercialization,of a broad range of prescription and ... the Company will present at the following,conferences:, ... held at the Grand Hyatt ...
... Agreement will enable HGS to generate revenue from available ... manufacturing capacity -, - Revenue potential from manufacturing alliances, including the alliance, ... ... years -, ROCKVILLE, Md., Sept. 4 Human Genome,Sciences, Inc. (Nasdaq: HGSI ) ...
... -- Company Maintains Full Year Guidance, ... International Limited (NYSE: MR ), a ... worldwide today announced its selected,unaudited financial results ... 2008.,During the quarter, Mindray successfully completed the ...
Cached Biology Technology:American Oriental Bioengineering Announces Participation in September Investor Conferences 2Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira 2Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira 3Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira 4Mindray Medical International Announces Second Quarter 2008 Results 2Mindray Medical International Announces Second Quarter 2008 Results 3Mindray Medical International Announces Second Quarter 2008 Results 4Mindray Medical International Announces Second Quarter 2008 Results 5Mindray Medical International Announces Second Quarter 2008 Results 6Mindray Medical International Announces Second Quarter 2008 Results 7Mindray Medical International Announces Second Quarter 2008 Results 8Mindray Medical International Announces Second Quarter 2008 Results 9Mindray Medical International Announces Second Quarter 2008 Results 10Mindray Medical International Announces Second Quarter 2008 Results 11Mindray Medical International Announces Second Quarter 2008 Results 12Mindray Medical International Announces Second Quarter 2008 Results 13Mindray Medical International Announces Second Quarter 2008 Results 14Mindray Medical International Announces Second Quarter 2008 Results 15Mindray Medical International Announces Second Quarter 2008 Results 16Mindray Medical International Announces Second Quarter 2008 Results 17
(Date:2/12/2015)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announced ... DISTRIBUTED METHOD AND SYSTEM TO IMPROVE COLLABORATIVE ... establishes NXT-ID,s position in the emerging "Internet of Things" ... for multiple devices to collaborate with one another to ...
(Date:2/5/2015)... PARK, North Carolina , 5. Februar ... 35. Jahr als spezialisiertes Logistikunternehmen und hat ... als einzige klinische Logistikfirma (Clinical Logistics Organization ... Kernbotschaft der neuen Kampagne lautet First ... Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... open letter addressed to President Barack Obama and the ... that the currently stated objectives in limiting the climatic ... to take clear leadership towards meet the objectives of ... to avert a "global climatic catastrophe". ...
... animals ever to have walked the face of the earth ... a paper published today in the Zoological Society of London,s ... the original statistical model used to calculate dinosaur mass is ... for the mass of Apatosaurus louisae , one of ...
... (June 21, 2009) Notch signaling helps determine the fate ... of organisms, including humans. In an article that appears in ... at Baylor College of Medicine report that a new finding ... in the fruit fly could explain the mystery behind an ...
Cached Biology News:Leading scientists and scholars urge action on climate issues 2Fate in fly sensory organ precursor cells could explain human immune disorder 2Fate in fly sensory organ precursor cells could explain human immune disorder 3